AGTX · XBRL financial data

Agentix financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (AGTX's year ends in late March)

In thousands of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 31, 2023	Q4 FY24†Mar 31, 2024	Q1 FY25†Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY26Jun 30, 2025	Q2 FY26Sep 30, 2025	Q3 FY26Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY27Jun 30, 2026
Research and development	58	(87)	46*	56	12	23	90*	100	25	0	0*	17
General and administrative	173	25	21*	19	17	17	17*	18	17	17	17*	17
Total operating expenses	353	16	(25)*	151	93	97	172*	200	123	67	54*	96
Operating income (loss)	(353)	(16)	25*	(151)	(93)	(97)	(172)*	(200)	(123)	(67)	(54)*	(96)
Interest expense	6	3	7*	8	10	11	14*	21	24	14	21*	22
Other income (expense)	(174)	(22)	28*	1	2	47	(98)*	15	(21)	—	—	(22)
Income tax expense (benefit)	0	0	0*	0	0	0	0*	0	0	0	0*	0
Net income (loss)	(179)	6	(3)*	(151)	(91)	(144)	(182)*	(186)	(144)	(79)	(77)*	(118)
Earnings per share, diluted USD per share	—	0.00	—	0.00	0.00	0.00	0.00*	0.00	0.00	0.00	0.00*	0.00
Weighted average shares, basic thousands of shares	—	40,067	—	—	—	40,067	—	—	—	—	—	—
Weighted average shares, diluted thousands of shares	—	—	—	40,067	40,067	40,067	40,067*	40,067	40,067	40,067	40,067*	40,067

† Share count changed about 1/4 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 4x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (AGTX's year ends in late March)

In thousands of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 31, 2023	Q4 FY24†Mar 31, 2024	Q1 FY25†Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY26Jun 30, 2025	Q2 FY26Sep 30, 2025	Q3 FY26Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY27Jun 30, 2026
Cash and cash equivalents	28	3	7	9	6	8	4	4	6	6	1	0
Prepaid and other current assets	306	108	100	158	164	146	96	0	0	0	0	0
Total current assets	334	112	106	167	170	154	100	4	6	6	1	0
Total assets	334	112	106	167	170	154	100	4	6	6	1	0
Accounts payable	1,439	1,106	962	1,070	1,128	1,067	969	700	712	707	716	713
Accrued liabilities	9	22	24	35	38	48	60	84	110	124	144	166
Total current liabilities	3,149	2,958	2,667	2,893	3,007	3,071	3,205	3,276	3,424	3,504	3,596	3,714
Total liabilities	3,149	2,958	2,667	2,893	3,007	3,071	3,205	3,276	3,424	3,504	3,596	3,714
Accumulated deficit	(5,958)	(5,951)	(5,954)	(6,105)	(6,196)	(6,340)	(6,522)	(6,707)	(6,851)	(6,930)	(7,007)	(7,125)
Total stockholders' equity	(2,815)	(2,846)	(2,560)	(2,726)	(2,837)	(2,917)	(3,104)	(3,272)	(3,418)	(3,498)	(3,596)	(3,714)
Total liabilities and equity	334	112	106	167	170	154	100	4	6	6	1	0
Common shares outstanding (cover page) thousands of shares	40,067	40,067	10,067	40,067	40,067	40,067	40,067	40,067	40,067	40,067	40,067	40,067

† Share count changed about 1/4 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 4x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (AGTX's year ends in late March)

In thousands of dollars	Q2 FY24Sep 30, 2023	Q3 FY24Dec 31, 2023	Q4 FY24†Mar 31, 2024	Q1 FY25†Jun 30, 2024	Q2 FY25Sep 30, 2024	Q3 FY25Dec 31, 2024	Q4 FY25Mar 31, 2025	Q1 FY26Jun 30, 2025	Q2 FY26Sep 30, 2025	Q3 FY26Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY27Jun 30, 2026
Net income (loss)	(179)	6	(3)*	(151)	(91)	(144)	(182)*	(186)	(144)	(79)	(77)*	(118)
Net cash from operating activities	56*	(37)*	(66)*	(2)	7*	(87)*	(43)*	(118)	3*	(8)*	15*	(26)
Net cash from investing activities	0*	0*	0*	0	0*	0*	0*	0	0*	0*	0*	0
Proceeds from issuing common stock	—	0*	0*	—	—	—	—	—	—	—	—	—
Repayments of long-term debt	—	0*	—	—	—	—	—	—	—	—	—	—
Net cash from financing activities	(50)*	50*	43*	20	10*	25*	45*	100	0*	10*	0*	26
Net change in cash	22*	(24)*	3*	3	(3)*	2*	(4)*	(0)	1*	1*	(6)*	(1)

† Share count changed about 1/4 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 4x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Agentix	0	not reported	(26)	40.1M	0.0 quarters	Q1 FY27 10-QJun 30, 2026
Evofem Biosciences	285	2,633	(3,140)*	132.5M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Galera Therapeutics	5,500	not reported	(875)	160.4M	6.3 quarters	Q1 FY26 10-QMar 31, 2026
ProtoKinetix	1.1	not reported	0.6*	411.6M	—	Q4 FY25 10-KDec 31, 2025
Regen BioPharma	0.2	59	(24)*	1.7B	0.0 quarters	Q3 FY26 10-QJun 30, 2026
Twinlab Consolidated Holdings	13	not reported	(907)*	259.1M	0.0 quarters	Q4 FY24 10-KDec 31, 2024
Decoy Therapeutics	8,289	228	(2,652)*	655,185	3.1 quarters	Q2 FY26 10-QJun 30, 2026
Hepion Pharmaceuticals	1,629	not reported	(1,394)*	90.2M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Nomad Power Solutions	12,670	not reported	(1,612)*	16.1M	7.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.